AI Bubble
← Back to feed

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Bubble signal: +1 · Overheating evidenceRelevance 74FundingUS
Source: TechCrunch AI · Published 2026-09-23

Summary

AI biotech company Enveda has raised $311 million, valuing the company at $2 billion. It is currently testing drugs for skin conditions and for preserving weight loss after patients stop taking GLP-1 drugs.

Bubble analysis

This is a concrete AI-linked funding round, adding to the money-inflow side of the bubble question and showing that AI branding still attracts large venture checks. But it is a single biotech company's round, far removed from the AI infrastructure capex-versus-revenue debate, so it speaks only indirectly to whether AI is in an investment bubble.

#valuation#funding#startup#biotech
Read original ↗

Related signals

linked by shared tags